Synthesis of NO-donor bisphosphonates and their in-vitro action on bone resorption

Journal of Medicinal Chemistry

Volumn 48, Issue 5, 2005, Pages 1322-1329

  Lazzarato, Loretta ^a   Rolando, Barbara ^a   Lolli, Marco L ^a   Tron, Gian Cesare ^b   Fruttero, Roberta ^a   Gasco, Alberto ^a   Deleide, Guido ^c   Guenther, Harald L ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Cyberonics Inc   (Italy)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(5,6 DINITROOXY 1 HYDROXYHEXYLIDENE)BIS(PHOSPHONIC ACID); (5,6 DINITROOXYHEXYLIDENE)BIS(PHOSPHONIC ACID); BISPHOSPHONIC ACID DERIVATIVE; HYDROXYAPATITE; NITRIC OXIDE; NITRIC OXIDE DONOR; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BONE LEVEL; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG MUSCLE LEVEL; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN FUNCTION; RAT; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; BONE RESORPTION; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; DIPHOSPHONATES; DURAPATITE; MALE; MEMBRANE GLYCOPROTEINS; MICE; NF-KAPPA B; NITRIC OXIDE DONORS; OSTEOCLASTS; RADIOPHARMACEUTICALS; RANK LIGAND; RATS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SODIUM PERTECHNETATE TC 99M; STEM CELLS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 14944365641     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040830d     Document Type: Article

References (48)

1. Palmer, R. M.; Ferrige, A. G.; Moncada, S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327, 524-526.
2. Moncada, S.; Higgs, A. The arginine nitric oxide pathway. N. Engl. J. Med. 1993, 329, 2002-2012.
3. Kerwin, J. F., Jr.; Heller, M. The arginine-nitric oxide pathway: a target for new drugs. Med. Chem. Res. 1994,14, 23-74.
4. Fukai, T.; Siegfried, M. R.; Ushio-Fukai, M.; Cheng, Y.; Kojda, G.; Harrison, D. C. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J. Clin. Invest. 2000, 105, 1631-1639.
5. Van't Hof, R. J.; Ralston, S. H. Nitric oxide and bone. Immunology 2001, 103, 255-261.
6. Takahash, N.; Udagawa, N.; Takami, M.; Suda, T. Cells in bone, osteoclast generation. In Principles of Bone Biology, 2nd ed.; Academic Press: San Diego, 2000; Vol. 1, pp 109-126.
7. Wang, P. G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A. J. Nitric oxide donors: chemical activities and biological applications. Chem. Rev. 2002, 102, 1091-1134.
8. Loscalzo, J.; Vita, J. A. Nitric Oxide and the Cardivascular System; Humana Press: Totowa, NJ, 2000.
9. Moncada, S.; Higgs, E. A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995, 9, 1319-1330.
10. Maclntyre, I.; Zaidi, M.; Towhidul, A. S. M.; Datta, H. K.; Moonga, B. S.; Lidbury, P. S.; Hecker, M.; Vane, J. R. Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2936-2940.
11. Mancini, L.; Moradi-Bihendi, N. M.; Becherini, L.; Martineti, V.; Maclntyre, I. The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent. Biochem. Biophys. Res. Commun. 2000, 274, 477-481.
12. Kasten, T. P.; Collin-Osdoby, P.; Patel, N.; Osdoby, P.; Krukowski, M.; Misko, T. P.; Settle, S. L.; Currie, M. G.; Nickols, G. A. Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3569-3573.
13. Hikiji, H.; Shin, W. S.; Oida, S.; Takato, T.; Koizumi, T.; Toyooka, T. Direct action of nitric oxide on osteoblastic differentiation. FEBS Lett. 1997, 410, 238-242.
14. Ostuka, E.; Hirano, K.; Matsushita, S.; Inoue, A.; Hirose, S.; Yamaguchi, A.; Hagiwara, H. Effects of nitric oxide from exogenous nitric oxide donors on osteoblastic metabolism. Eur. J. Pharmacol. 1998, 349, 345-350.
15. Baldik, Y.; Talu, U.; Bilge, H.; Demiryont, M.; Toker, G. A. Bone healing regulated by nitric oxide. An experimental study. Clin. Orthop. Relat. Res. 2002, 404, 343-352.
16. Wimalawansa, S. J.; De Marco, G.; Gangula, P.; Yallampalli, C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1998, 18, 301-304.
17. Burney, S.; Tamir, S.; Gal, A.; Tannenbaum, S. R. A mechanistic analysis of nitric oxide-induced cellular toxicity. Nitric Oxide: Biol. Chem. 1997, 1, 130-144.
18. Fleisch, H. Bisphosphonates in Bone Diseases, 3rd ed.; The Parthenon Publishing Group Inc.: New York, 1997.
19. Sunberg, R. J.; Ebetino, F. H.; Mosher, C. T.; Roof, C. F. Designing drugs for stronger bones. CHEMTECH 1991, 304-309.
20. Esswein, A.; Bauss, F.; Muehlbauer, R.; Guenther, H.; Bosies, E. Bisphosphonates and novel related structural classes for bone resorption disorders. Phosphorous, Sulfur Silicon 1999, 144-146, 9-13.
21. Uludag, H. Bisphosphonates as a fundation of drug delivery to bone. Curr. Pharm. Des. 2002, 8, 1929-1944.
22. Lundy, K. M.; Clark, M. T. EP 0, 984, 012, 2000; Chem. Abstr. 2001, 135, 152718.
23. Boschan, R.; Merrow, R. T.; Van Dolah, R. W. The chemistry of nitrate esters. Chem. Rev. 1955, 55, 485-510.
24. Lolli, M. L.; Lazzarato, L.; Di Stilo, A.; Fruttero, R.; Gasco, A. Michael addition of Grignard reagents to tetrethyl ethenylidene-bisphosphonate. J. Organomet. Chem. 2002, 650, 77-83.
25. Vepsäläinen, J.; Nupponen, H.; Pohjala, E.; Ahlgren, M.; Vainiotalo, P. Bisphosphonic compounds. Part 3. Preparation and identification of tetraalkyl methylene- and (α-halomethylene)-bisphosphonates by mass spectrometry, NMR spectroscopy and X-ray crystallography. J. Chem. Soc., Perkin Trans. 2 1992, 2, 835-842.
26. Günther, H. The influence of molecular symmetry and chirality on proton magnetic resonance spectra. NMR Spectroscopy, 2nd ed.; John Wiley & Sons: New York, 1995; pp 199-219.
27. 2+. Z. Naturforsch. 1978, 31, 661-663.
28. Cohen, H.; Solomon, V.; Alferiev, I. S.; Breuer, E.; Ornoy, A.; Patlas, N.; Eidelman, N.; Hägele, G.; Golomb, G. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders. Pharm. Res. 1998, 15, 606-613.
29. Luckman, S. P.; Hughes, D. E.; Coxon, F. P.; Russell, R. G. G.; Rogers, M. J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 1998, 13, 581-589.
30. Fisher, J. E.; Rogers, M. J.; Halasy, J. M.; Luckmann, S. P.; Guges, D. E.; Masarachia, P. J.; Wesolowski, G.; Russell, R. G.; Reszka, A. A. Alendronate mechanism of action: geranylgeraniol an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 133-138.
31. Rogers, M. J. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Curr. Pharm. Des. 2003, 9, 2643-2658.
32. Sahni, M.; Guenther, H. L.; Fleisch, H.; Collin, P.; Martin, T. J. Bisphosphonates act on rat resorption through the mediation of osteoblasts. J. Clin. Invest. 1993, 91, 2004-2011.
33. Vitté, C.; Fleisch, H.; Guenther, H. L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996, 137, 2324-2333.
34. Halsay-Nagy, J. M.; Rodan, G. A.; Reszka, A. A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29, 553-559.
35. Rodan, G. A.; Fleisch, H. Bisphosphonates: mechanism of action. J. Clin. Invest. 1998, 97, 2692-2696.
36. Hughes, D. E.; MacDonald, B. R.; Russell, R. G. G.; Gowen, M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term culture of human bone marrow. J. Clin. Invest. 1989, 83, 1930-1935.
37. Huber, D. M.; Bendixen, A. C.; Pathrose, P.; Srivastava, S.; Dienger, K. M.; Sevde, N. K.; Pike, J. W. Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 2001, 142, 3800-3808.
38. Choi, S. J.; Kurihara, N.; Oba, Y.; Roodman, G. D. Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. J. Bone Miner. Res. 2001, 16, 1804-1811.
39. Yasuda, H.; Shima, N.; Nakagawa, N.; Yamaguchi, K.; Kinosaki, M.; Mochizuki, S.-I.; Tomoyasu, A.; Yano, K.; Goto, M.; Murakami, A.; Tsuda, E.; Morinaga, T.; Higashio, K.; Udagawa, N.; Takahashi, N.; Suda, T. Osteoclast differentiation factor is a ligand forosteoprotegerin/osteoclastogenesis- inhibitory factor and it is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3597-3602.
40. Schrammel, A.; Behrends, S.; Schmidt, K.; Koesling, D.; Mayer, B. Characterization of 1H-[1,2,4]oxadiazolo[4,3a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol. Pharmacol. 1996, 50, 1-5.
41. Jork, H.; Funk, W.; Fischer, W.; Wimmer, H. Thin-Layer Chromatography; VCH: Weinheim, Germany, 1990; Vol. 1a, pp 170-172.
42. Hutchinson, D. W.; Semple, G. Synthesis of alkilated methylene bisphosphonate via organotallium intermediates. J. Organomet. Chem. 1985, 291, 145-151.
43. Martin, M. B.; Grimley, J. S.; Lewis, J. C.; Heath, H. T.; Bailey, B. N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N. J.; Docampo, R.; Croft, S. L.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Tripanosoma cruzi, Leishmania donovani, Toxoplasma condii, and Plasmodium falciparum: a potential route to chemotherapy. J. Med. Chem. 2001, 44, 909-916.
44. De la Mare, H. E.; Kochi, J. K.; Rust, F. F. The oxidation and reduction of free radicals by metal salts. J. Am. Chem. Soc. 1963, 85, 1437-1449.
45. Degenhardt, C. R.; Burdsall, D. C. Synthesis of ethenylidenebis- (phosphonic acid) and ist tetraalkyl esters. J. Org. Chem. 1986, 51, 3488-3490.
46. Lehmkuhl, H.; Mehler, K. Addition of organomagnesium halides to carbon-carbon bonds, XII. Addition of alkylmagnesium halides to 3,3-dimethylcyclopropene; a new route to cis- or transchrysanthemic acid. Liebigs Ann. Chem. 1978, 11, 1841-1853.
47. Watson, S. C.; Eastham, J. F. Colored indicators for simple direct titration of magnesium and lithium reagents. J. Organomet. Chem. 1967, 9, 165-168.
48. Avdeef, A. Refinement of partition coefficients and ionization constants of multiprotic substances. J. Pharm. Sci. 1993, 82, 183-190.